Gut microbiome and its role in cardiovascular diseases.

Gut microbiome and its role in cardiovascular diseases.
复制标题

DOI:
10.1097/hco.0000000000000445
复制
发表时间:
2017-11
影响因子:
2.3
通讯作者:
Tang WHW
Tang WHW
中科院分区:
医学4区
文献类型:
--
作者:
Ahmadmehrabi S;Tang WHW

文献摘要

被引文献

相似文献

近年来,由于许多关于肠道细菌对人类健康和疾病的影响的发现,对肠道微生物-宿主相互作用的兴趣有所增加。生态失调是肠道微生物群组成的变化,与许多病理学有关,包括心血管疾病(CVD)。本文将回顾肠道微生物组的正常功能,其与CVD的联系以及潜在的治疗干预措施。最近发现的肠道微生物群衍生分子在心脏病及其危险因素的发展中的作用显着增加了人们对肠道和心脏之间联系的关注。肠道微生物组实际上是一个内分泌器官,可以说是最大的,能够促进和反应宿主内的循环信号分子。肠道微生物-宿主相互作用通过许多途径发生,包括三甲胺-N-氧化物(TMAO)和短链脂肪酸(SCFA)。这些分子和其他分子与许多病理学有关,包括慢性肾病、动脉粥样硬化和高血压。虽然我们对肠道微生物与宿主相互作用的理解最近有所增加,但关于肠道微生物组与CVD之间的机械联系仍存在许多问题。随着进一步的研究,我们可能有一天能够将肠道微生物群作为CVD的可评估风险因素,并针对肠道微生物群进行靶向治疗。
In recent years, an interest in intestinal microbiota-host interactions has increased due to many findings about the impact of gut bacteria on human health and disease. Dysbiosis, a change in the composition of the gut microbiota, has been associated with much pathology, including cardiovascular diseases (CVD). This article will review normal functions of the gut microbiome, its link to CVD, and potential therapeutic interventions. The recently discovered contribution of gut microbiota-derived molecules in the development of heart disease and its risk factors has significantly increased attention towards the connection between our gut and heart. The gut microbiome is virtually an endocrine organ, arguably the largest, capable of contributing to and reacting to circulating signaling molecules within the host. Gut microbiota-host interactions occur through many pathways, including trimethylamine-N-oxide (TMAO) and short chain fatty acids (SCFA). These molecules and others have been linked to much pathology including chronic kidney disease, atherosclerosis, and hypertension. Although our understanding of gut microbiota-host interactions has increased recently, many questions remain about the mechanistic links between the gut microbiome and CVD. With further research, we may one day be able to add gut microbiota profiles as an assessable risk factor for CVD and target therapies towards the gut microbiota.